News | May 21, 2007

HemoSense To Supply LabCorp with INRatio System

San Jose, CA - HemoSense, Inc.. recently announced that it has signed an agreement with Laboratory Corporation of America Holdings (LabCorp) to supply the HemoSense portable INRatio PT/INR monitoring system to identified LabCorp laboratories. The INRatio system will also be made available to selected LabCorp patient service centers and affiliated physician offices nationwide.

HemoSense's INRatio system consists of a small, portable meter and disposable test strips that provide a quick and accurate measurement of blood-clotting time, known as a PT/INR value. This test helps patients reduce the risk of strokes through frequent monitoring of anticoagulation therapy.

"We are delighted to be working with a recognized laboratory leader, and this agreement with LabCorp is one more step toward our goal of increasing the HemoSense share of a growing market in patient blood coagulation monitoring," said Timothy Still, executive VP and chief commercial officer of HemoSense. "Monitoring patients' PT/INR levels at the point-of-care can help improve the treatment, health and lifestyle of patients taking warfarin."

According to the U.S. Centers for Medicare & Medicaid Services (CMS), monthly blood coagulation testing is inadequate for the majority of patients on chronic warfarin therapy. HemoSense's INRatio system reduces the time and inconvenience required to manage warfarin and allows patients to play an active role in management of their warfarin dosage, encouraging optimal patient compliance, more time spent within the patient's therapeutic range and immediate dose management. The INRatio system is based on a reliable proprietary electrochemical technology that generates rapid PT/INR results simultaneously with two levels of quality control from a single drop of blood. Patient training is straightforward and test strips can be stored at room temperature for up to one year.

Tests performed using the INRatio system in the point-of-care setting are currently reimbursed by Medicare and private payers for all patients on warfarin. The INRatio system is sold through a prestigious and growing network of distributors in the U.S. and internationally in 23 countries.

SOURCE: HemoSense, Inc